Vericel Corp (VCEL) Shares Bought by Mutual of America Capital Management LLC
Mutual of America Capital Management LLC lifted its position in shares of Vericel Corp (NASDAQ:VCEL) by 1.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 409,754 shares of the biotechnology company’s stock after purchasing an additional 5,914 shares during the period. Mutual of America Capital Management LLC owned about 0.95% of Vericel worth $5,798,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of VCEL. Capital Fund Management S.A. acquired a new stake in shares of Vericel during the second quarter worth about $104,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of Vericel during the second quarter worth about $108,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Vericel during the second quarter worth about $116,000. Commonwealth Equity Services LLC acquired a new stake in shares of Vericel during the second quarter worth about $123,000. Finally, Metropolitan Life Insurance Co. NY acquired a new stake in shares of Vericel during the second quarter worth about $128,000. Institutional investors and hedge funds own 79.31% of the company’s stock.
In related news, insider Dominick Colangelo sold 75,000 shares of the business’s stock in a transaction dated Thursday, October 4th. The stock was sold at an average price of $15.02, for a total value of $1,126,500.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Gerard J. Michel sold 15,000 shares of the business’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $12.35, for a total value of $185,250.00. Following the completion of the transaction, the chief financial officer now owns 165,960 shares in the company, valued at approximately $2,049,606. The disclosure for this sale can be found here. Insiders sold a total of 178,500 shares of company stock worth $2,660,375 in the last 90 days. 3.30% of the stock is currently owned by insiders.
Shares of VCEL stock opened at $16.93 on Friday. Vericel Corp has a 52-week low of $4.45 and a 52-week high of $18.87. The company has a current ratio of 7.96, a quick ratio of 7.71 and a debt-to-equity ratio of 0.14.
Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.09. The firm had revenue of $22.50 million for the quarter, compared to analysts’ expectations of $18.14 million. Vericel had a negative return on equity of 17.39% and a negative net margin of 15.80%. The company’s revenue for the quarter was up 57.3% compared to the same quarter last year. On average, analysts anticipate that Vericel Corp will post -0.23 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/vericel-corp-vcel-shares-bought-by-mutual-of-america-capital-management-llc/2670434.html.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.
Recommended Story: How Investors Use a Balance Sheet
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.